Children's Hormone Foundation

© 2014 The Maria New Children's Hormone Foundation 
​An exempt organization qualified under section 501 C(3) of the Internal Revenue Code 

Dr. New has developed prenatal diagnosis and treatment for CAH since 1984. Dr. New directs a service that provides advice to physicians worldwide who are offering prenatal diagnosis and treatment for severe classical CAH. Dr. Maria New has treated the largest number of mothers at risk of having children with CAH. She has treated over 800 pregnant women at risk for the birth of a CAH-affected child. Treatment begins as soon as pregnancy is confirmed. 

Prenatal diagnosis of affected newborns can only be made by invasive methods, amniocentesis and chorionic villus sampling.  Dr. New and her team have developed and published a new noninvasive method to make the prenatal diagnosis of CAH by simply taking blood from the mother at 7 weeks of pregnancy. If successful, all invasive procedures for prenatal diagnosis will be eliminated. This will simplify and reduce the cost of prenatal diagnosis and improve prenatal treatment of CAH.


Dr. New maintains contact with all children treated prenatally and has not found permanent adverse effects of treatment on mother or fetus. Thus, with nearly 30 years experience, the treatment has been found safe for mother and child. 

Congenital adrenal hyperplasia (CAH) refers to a family of inherited disorders caused by defects in the enzymes of the adrenal gland required for synthesis of the hormone cortisol. The most common type of CAH results from low production of the enzyme 21-hydroxylase. A classically affected fetus is exposed to high levels of androgens in utero as a result of 21-hydroxylase deficiency. 

Dr. New pioneered prenatal diagnosis of CAH and prenatal treatment of classical CAH. She has the only clinic in the United States which routinely provides this service. Prenatal treatment of classically affected females prevents development of ambiguous genitalia as a result of exposure to high levels of androgens in utero. Prenatal treatment prevents the development of genital ambiguity in females affected with severe CAH, thus avoiding the need for reconstructive genital surgery.

Prenatal diagnosis of affected children of both sexes enables families at risk to ensure optimal care of newborns. 


PublicationThe Journal of Clinical Endocrinology & Metabolism

Non-invasive Prenatal Diagnosis & Treatment